Cell-penetrating peptides are evolving from general cell-entry tools to precision delivery systems that can target drugs to specific organelles like mitochondria and nuclei.
Tissue → Cell → OrganelleDrug delivery is evolving from targeting tissues, to targeting specific cells, to now targeting specific organelles within cells using cell-penetrating peptide technologies
What the researchers found
Cell-penetrating peptides conjugated with organelle-targeting sequences represent an advancing strategy for intracellular drug delivery. The review summarizes how CPPs can be engineered to deliver cargo to specific subcellular compartments including mitochondria, nuclei, endoplasmic reticulum, and lysosomes. This organelle-level targeting moves drug delivery beyond tissue-level or cell-level precision, improving therapeutic efficacy while reducing off-target toxicity and potentially overcoming drug resistance mechanisms.
Why it matters
Many drugs fail not because they can't reach the right cell, but because they can't reach the right compartment within the cell. For example, some cancer drugs need to reach the nucleus to damage DNA, while others target mitochondria to trigger cell death. CPPs that can deliver drugs directly to these organelles could dramatically improve treatment outcomes for cancer, neurological diseases, and metabolic disorders while reducing the doses needed and minimizing side effects.
How the study worked
This is a narrative review article that summarizes published literature on cell-penetrating peptides and their intracellular organelle-targeting capabilities. The authors reviewed current targeting strategies, CPP/cargo complex designs, and pharmacological/therapeutic applications reported in the field through early 2022.
What this study cannot tell us
As a review article, this paper does not present new experimental data. The field of CPP-mediated organelle targeting is still largely preclinical, with limited clinical validation. Many of the targeting strategies described work well in cell culture but face challenges with in vivo delivery, including stability, immunogenicity, and biodistribution. The review may also reflect the publication bias toward positive results in the CPP literature.
How to read the evidence
This is a narrative review article that synthesizes existing literature rather than presenting new data. While reviews provide valuable overviews of a field, they are not primary evidence and may be subject to author selection bias in the studies covered.
When this study was published
Published in 2022, this review captures the state of CPP research through early 2022. The field moves quickly, and newer targeting strategies and clinical applications may have emerged since publication.
The bigger picture
Cell-penetrating peptides have been studied for over two decades, but the shift from general cell entry to organelle-specific delivery represents a significant maturation of the field. As drug development increasingly focuses on intracellular targets — particularly in oncology and gene therapy — precision delivery at the organelle level could become essential. CPP-based delivery systems may complement or compete with lipid nanoparticles and other delivery technologies.
Questions still open
- Which organelle-targeting CPP strategies are closest to clinical translation, and what barriers remain?
- How do CPP-based delivery systems compare to lipid nanoparticles and antibody-drug conjugates for intracellular targeting?
- Can organelle-targeted CPPs effectively overcome multidrug resistance in cancer by bypassing efflux pump mechanisms?
Common questions
What are cell-penetrating peptides?
Why does it matter which organelle a drug reaches inside a cell?
Read the original research
An update on cell-penetrating peptides with intracellular organelle targeting.
Expert opinion on drug delivery, 19(2), 133-146
Citation
Cerrato, Carmine Pasquale; Langel, Ülo. (2022). An update on cell-penetrating peptides with intracellular organelle targeting.. Expert opinion on drug delivery, 19(2), 133-146. https://doi.org/10.1080/17425247.2022.2034784